Home >> ALL ISSUES >> 2017 Issues >> Clinical Pathology Abstracts, 2/17

Clinical Pathology Abstracts, 2/17

image_pdfCreate PDF

Editor: Deborah Sesok-Pizzini, MD, MBA, professor, Department of Clinical Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, and chief, Division of Transfusion Medicine, Children’s Hospital of Philadelphia.

Screening for Babesia microti in the U.S. blood supply

Babesia microti is a tickborne intraerythrocytic parasite that may be transmitted through blood transfusions. Babesia infection may range from an asymptomatic infection in a healthy person to a fatal infection in an immunocompromised person. Concern about bloodborne transmission of B. microti from infected donors is increasing. From 1979 to 2009, 162 cases of transfusion-transmitted babesiosis were reported, of which 159 were caused by B. microti. There is no FDA licensed test for screening for B. microti in donated blood. Donor screening consists of asking donors if they have ever had babesiosis; those that answer “yes” are deferred indefinitely. This screening method is considered to be very ineffective. The authors conducted a study to assess data from a large-scale investigational product-release testing protocol and donor follow-up program. From June 2012 through September 2014, they performed arrayed fluorescence immunoassays for B. microti antibodies and real-time polymerase chain-reaction (PCR) assays for B. microti DNA on blood samples obtained in Connecticut, Massachusetts, Minnesota, and Wisconsin. Of 89,153 blood donation samples tested, 335 were confirmed to be positive, of which 67 were PCR positive. Only nine samples were antibody negative, which represented 13 percent of all PCR-positive samples. PCR-positive samples were identified throughout the year, while antibody-negative infections occurred from June through September. Donor follow-up showed DNA clearance in 86 percent of the donors but antibody seroreversion in only eight percent after one year. Overall, 29 cases of transfusion-transmitted babesiosis were linked to blood from infected donors, including blood from 10 donors whose samples were PCR positive two to seven months after the implicated donation. The authors concluded that blood donation screening for antibodies to B. microti and DNA from the parasite was associated with a decreased risk of transfusion-transmitted babesiosis. Data from this study may help provide a potential blood donor testing strategy for preventing transfusion-transmitted babesiosis.

Moritz ED, Winton CS, Tonnetti L, et al. Screening for Babesia microti in the U.S. blood supply. N Engl J Med. 2016;375:2236–2245.

Correspondence: Dr. Susan Stramer at susan.stramer@redcross.org

Perspectives on whether WES is ethically disruptive in pediatrics

CAP TODAY
X